百济神州ADC肿瘤新药在中国获批临床!

康可药研
20 Dec 2024

本文仅供信息分享,不构成用药或治疗或投资推荐。因编辑水平有限,如有错误或不是最新信息感谢指出!今日(12月19日),中国国家药监局药品审评中心(CDE)官网公示,百济神州申报的1类新药注射用BG-C137获批临床,拟开发用于晚期实体瘤患者。公开资料显示,BG-C137是一款靶向FGFR2b的抗体偶联药物(ADC),百济神州拟开发该产品用于上消化道瘤种和乳腺癌。根据CDE官网查询,本次为该产品首次在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10